Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by gojotv!on Nov 29, 2021 10:52pm
310 Views
Post# 34178533

The cure for cancer...

The cure for cancer......could not have come at a better time.
I was hoping that the "optimized" (but really, correct) treatment would yield better results than those seen in the original 12 undertreated patients, and it has.
These results point to the possibility of TLT's treatment becoming the standard, as it is a) non-toxic and b) highly effective.
Nothing prevents a physician from choosing repeat treatments.
The study limits treatment to 2 sessions. For scientific purposes, all must have the same number of treatments and a larger pool of patients gives better statistical granularity.
But in real life, you can just keep treating intil the cancer responds and/or goes away completely.
Think of the bladders that could be saved!
Not just excited for my pocketbook. I'm thinking now of Gebremeskel and other posters who have shown up here telling us of their struggle against bladder cancer.
Crossing my fingers that they can find their way into this study soon.
And this bodes oh-so-well for pending studies for other cancer indications... glioblastoma, lung, etc.
All-in-all, a breakthrough in my books!
Let's see if the FDA agrees, and how quickly they do so.
It's going to be a great holiday season.


<< Previous
Bullboard Posts
Next >>